OrbiMed’s Natera NTRA Stock Holding History

OrbiMed’s Portfolio NTRA Stock Details NTRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-150,000	Closed	-$5.32M	–	141
2022 Q2	$5.32M	Hold	150,000	–	–	0.1%	111
2022 Q1	$6.1M	Buy	+150,000	New	+$9.01M	0.1%	114

Other funds holding NTRA

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DFO

Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

OrbiMed's NTRA Position: Q2 2026 in Review

OrbiMed held its Natera (NTRA) position steady in Q2 2026 at 262,000 shares worth $71.1M. The position accounts for 1.32% of the portfolio, ranked #20.

OrbiMed first reported a position in NTRA in Q3 2015 and has held it in 44 quarters since. The position peaked at $234M in Q2 2021. 847 funds tracked by Wall St. Rank hold NTRA as of Q2 2026.

OrbiMed held 262,000 shares of Natera worth $71.1M as of Q2 2026.
OrbiMed left its Natera share count unchanged in Q2 2026.
Natera made up 1.32% of OrbiMed's portfolio in Q2 2026, its #20 holding.
OrbiMed first reported a position in Natera in Q3 2015 and has held it in 44 quarters since.
OrbiMed's Natera position peaked at $234M in Q2 2021.
847 funds tracked by Wall St. Rank held Natera as of Q2 2026.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.